Table 1 Statistical analysis shows choice of CPT or LP method is not the major contributor to variance for all parameters measured. Anova variance for contribution of donor, method (CPT or LP), and operator on yield and viability, cell population distribution (populations), and stimulated cytokine expression in CD4+ and CD8+ T cells (CEF stimulated, PMA-I stimulated). Sum squares, sum square contributions, F values, and P values are show for each parameter measured (rows)
From: Functional comparison of PBMCs isolated by Cell Preparation Tubes (CPT) vs. Lymphoprep Tubes
Yield and Viability | Populations | Populations | |||||||||||||||
WilcoxonPValue | Sum Square | Sum Square Contribution | ANOVAFValue | ANOVAPValue | WilcoxonPValue | Sum Square | Sum Square Contribution | ANOVAFValue | ANOVAPValue | WilcoxonPValue | Sum Square | Sum Square Contribution | ANOVAFValue | ANOVAPValue | |||
Cells/mL Pre Freeze | Monocytes | Memory CD4+ | |||||||||||||||
Method | 9.77E-02 | 1.11E+ 12 | 21.4% | 6.49 | 2.56E-02 | Method | 5.73E-01 | 9.34E-01 | 0.4% | 0.34 | 5.70E-01 | Method | 3.01E-01 | 8.93E-02 | 0.0% | 0.04 | 8.45E-01 |
Donor | 3.65E+ 12 | 70.8% | 10.73 | 2.13E-03 | Donor | 2.43E+ 02 | 94.0% | 44.57 | 2.79E-06 | Donor | 9.39E+ 02 | 98.3% | 209.59 | 4.65E-10 | |||
Operator | 4.01E+ 11 | 7.8% | 1.18 | 3.41E-01 | Operator | 1.45E+ 01 | 5.6% | 2.66 | 1.10E-01 | Operator | 1.65E+ 01 | 1.7% | 3.68 | 5.66E-02 | |||
Cells/mL Post Freeze | Lymphocytes | Naïve CD4+ | |||||||||||||||
Method | 1.29E-01 | 2.42E+ 11 | 9.7% | 3.39 | 9.06E-02 | Method | 4.26E-01 | 1.60E+ 00 | 0.4% | 0.60 | 4.53E-01 | Method | 4.26E-01 | 1.02E+ 00 | 0.1% | 0.61 | 4.50E-01 |
Donor | 2.15E+ 12 | 86.3% | 15.07 | 5.33E-04 | Donor | 3.40E+ 02 | 95.0% | 63.76 | 4.05E-07 | Donor | 1.19E+ 03 | 99.3% | 355.42 | 2.09E-11 | |||
Operator | 1.01E+ 11 | 4.0% | 0.70 | 5.14E-01 | Operator | 1.61E+ 01 | 4.5% | 3.03 | 8.62E-02 | Operator | 6.94E+ 00 | 0.6% | 2.07 | 1.68E-01 | |||
% Recovery | NK Cells | Memory CD4- | |||||||||||||||
Method | 1.29E-01 | 7.26E+ 01 | 12.0% | 2.47 | 1.42E-01 | Method | 8.23E-01 | 8.48E-01 | 0.5% | 0.31 | 5.91E-01 | Method | 2.50E-01 | 1.61E+ 00 | 0.6% | 1.39 | 2.62E-01 |
Donor | 2.93E+ 02 | 48.4% | 4.97 | 2.68E-02 | Donor | 1.69E+ 02 | 95.5% | 30.39 | 2.01E-05 | Donor | 2.74E+ 02 | 98.2% | 118.24 | 1.27E-08 | |||
Operator | 2.40E+ 02 | 39.6% | 4.07 | 4.48E-02 | Operator | 7.15E+ 00 | 4.0% | 1.29 | 3.12E-01 | Operator | 3.42E+ 00 | 1.2% | 1.47 | 2.68E-01 | |||
Viability Pre Freeze | T Cells | Naïve CD4- | |||||||||||||||
Method | 1.64E-01 | 2.05E+ 01 | 26.6% | 3.72 | 7.79E-02 | Method | 9.77E-02 | 9.44E+ 00 | 5.8% | 3.08 | 1.05E-01 | Method | 2.50E-01 | 3.40E+ 00 | 2.0% | 2.35 | 1.51E-01 |
Donor | 9.17E+ 00 | 11.9% | 0.83 | 4.59E-01 | Donor | 1.22E+ 02 | 74.5% | 19.87 | 1.55E-04 | Donor | 1.51E+ 02 | 90.4% | 52.13 | 1.21E-06 | |||
Operator | 4.73E+ 01 | 61.5% | 4.29 | 3.92E-02 | Operator | 3.22E+ 01 | 19.7% | 5.26 | 2.29E-02 | Operator | 1.25E+ 01 | 7.5% | 4.34 | 3.83E-02 | |||
Viability Post Freeze | B Cells | ||||||||||||||||
Method | 9.77E-02 | 1.79E+ 01 | 58.7% | 4.10 | 6.56E-02 | Method | 3.59E-01 | 1.23E-01 | 0.9% | 0.27 | 6.12E-01 | ||||||
Donor | 8.18E+ 00 | 26.8% | 0.94 | 4.18E-01 | Donor | 1.24E+ 01 | 92.7% | 13.76 | 7.84E-04 | ||||||||
Operator | 4.41E+ 00 | 14.5% | 0.51 | 6.15E-01 | Operator | 8.63E-01 | 6.4% | 0.95 | 4.13E-01 | ||||||||
CEF Stimulated | PMA-I Stimulated | Unstimulated | |||||||||||||||
WilcoxonPValue | Sum Square | Sum Square Contribution | ANOVAFValue | ANOVAPValue | WilcoxonPValue | Sum Square | Sum Square Contribution | ANOVAFValue | ANOVAPValue | WilcoxonPValue | Sum Square | Sum Square Contribution | ANOVAFValue | ANOVAPValue | |||
CD4 + IFNg+ | CD4 + IFNg+ | CD4 + IFNg+ | |||||||||||||||
Method | 8.20E-01 | 2.80E-06 | 0.4% | 0.19 | 6.74E-01 | Method | 4.96E-01 | 7.70E-01 | 0.7% | 0.52 | 4.87E-01 | Method | 9.10E-01 | 2.94E-07 | 0.0% | 0.03 | 8.69E-01 |
Donor | 7.74E-04 | 97.9% | 25.65 | 4.64E-05 | Donor | 1.08E+ 02 | 99.0% | 36.09 | 8.39E-06 | Donor | 6.38E-04 | 99.1% | 30.97 | 1.83E-05 | |||
Operator | 1.40E-05 | 1.8% | 0.46 | 6.40E-01 | Operator | 3.10E-01 | 0.3% | 0.10 | 9.02E-01 | Operator | 5.31E-06 | 0.8% | 0.26 | 7.77E-01 | |||
CD4 + IL-17+ | CD4 + IL-17+ | CD4 + IL-17+ | |||||||||||||||
Method | 6.73E-01 | 5.00E-09 | 0.1% | 0.01 | 9.10E-01 | Method | 4.96E-01 | 2.35E-02 | 2.1% | 0.38 | 5.48E-01 | Method | 5.79E-02 | 4.36E-07 | 27.8% | 3.20 | 9.87E-02 |
Donor | 3.30E-06 | 81.2% | 4.43 | 3.63E-02 | Donor | 1.03E+ 00 | 92.8% | 8.36 | 5.31E-03 | Donor | 7.60E-07 | 48.4% | 2.80 | 1.01E-01 | |||
Operator | 7.60E-07 | 18.7% | 1.02 | 3.90E-01 | Operator | 5.57E-02 | 5.0% | 0.45 | 6.46E-01 | Operator | 3.73E-07 | 23.8% | 1.37 | 2.90E-01 | |||
CD4 + IL-4+ | CD4 + IL-4+ | CD4 + IL-4+ | |||||||||||||||
Method | 1.64E-01 | 6.47E-04 | 53.1% | 1.71 | 2.16E-01 | Method | 2.50E-01 | 4.74E-01 | 8.3% | 1.83 | 2.01E-01 | Method | 4.26E-01 | 2.55E-04 | 8.8% | 0.44 | 5.18E-01 |
Donor | 3.53E-04 | 28.9% | 0.47 | 6.38E-01 | Donor | 4.92E+ 00 | 86.3% | 9.50 | 3.36E-03 | Donor | 1.38E-03 | 47.7% | 1.21 | 3.33E-01 | |||
Operator | 2.20E-04 | 18.0% | 0.29 | 7.53E-01 | Operator | 3.08E-01 | 5.4% | 0.59 | 5.68E-01 | Operator | 1.27E-03 | 43.6% | 1.10 | 3.63E-01 | |||
CD8 + IFNg+ | CD8 + IFNg+ | CD4-IFNg+ | |||||||||||||||
Method | 3.74E-01 | 1.49E-03 | 0.2% | 0.11 | 7.45E-01 | Method | 3.59E-01 | 1.61E+ 01 | 0.4% | 1.01 | 3.35E-01 | Method | 6.78E-01 | 1.20E-05 | 9.5% | 0.78 | 3.93E-01 |
Donor | 9.01E-01 | 91.6% | 33.38 | 1.25E-05 | Donor | 4.09E+ 03 | 99.3% | 128.58 | 7.85E-09 | Donor | 8.00E-06 | 6.3% | 0.26 | 7.74E-01 | |||
Operator | 8.09E-02 | 8.2% | 3.00 | 8.80E-02 | Operator | 1.39E+ 01 | 0.3% | 0.44 | 6.55E-01 | Operator | 1.07E-04 | 84.2% | 3.49 | 6.38E-02 | |||
CD8 + IL-17+ | CD8 + IL-17+ | CD4-IL-17+ | |||||||||||||||
Method | 1.98E-01 | 6.81E-07 | 20.2% | 3.65 | 8.04E-02 | Method | 3.01E-01 | 1.77E-03 | 3.8% | 1.07 | 3.20E-01 | Method | 4.19E-01 | 1.28E-06 | 17.4% | 1.77 | 2.08E-01 |
Donor | 2.43E-06 | 71.9% | 6.52 | 1.21E-02 | Donor | 4.06E-02 | 85.9% | 12.28 | 1.25E-03 | Donor | 5.61E-06 | 76.2% | 3.88 | 5.03E-02 | |||
Operator | 2.68E-07 | 7.9% | 0.72 | 5.08E-01 | Operator | 4.91E-03 | 10.4% | 1.49 | 2.65E-01 | Operator | 4.74E-07 | 6.4% | 0.33 | 7.27E-01 | |||
CD8 + IL-4+ | CD8 + IL-4+ | CD4-IL-4+ | |||||||||||||||
Method | 7.34E-01 | 1.02E-04 | 9.9% | 0.31 | 5.87E-01 | Method | 3.59E-01 | 6.41E-03 | 0.0% | 0.07 | 7.92E-01 | Method | 1.00E+ 00 | 1.72E-05 | 0.4% | 0.02 | 8.85E-01 |
Donor | 4.89E-04 | 47.5% | 0.74 | 4.96E-01 | Donor | 1.62E+ 01 | 98.6% | 91.81 | 5.33E-08 | Donor | 2.95E-03 | 73.3% | 1.86 | 1.99E-01 | |||
Operator | 4.37E-04 | 42.5% | 0.67 | 5.32E-01 | Operator | 2.16E-01 | 1.3% | 1.23 | 3.27E-01 | Operator | 1.05E-03 | 26.2% | 0.66 | 5.33E-01 | |||